Recurrent Aphthous Stomatitis (original) (raw)

Continuing Education Activity

Recurrent aphthous stomatitis (RAS), commonly called "canker sores," is a perplexing oral condition characterized by the recurrent development of painful aphthous ulcers on non-keratinized oral mucous membranes. This condition poses a significant challenge to patients and healthcare professionals due to its uncertain etiology. Patients often report a family history of RAS, suggesting a genetic predisposition. Factors such as local trauma, stress, smoking cessation, anemia, and hematinic deficiency have also been linked to the occurrence of RAS. Gastrointestinal conditions like Crohn's disease, ulcerative colitis, and malabsorption diseases, including celiac disease, are associated with the development of oral aphthous ulcers. RAS is a possible clinical manifestation of more severe conditions like Behçet's disease or HIV infection, making early diagnosis and management critical.

This activity offers a comprehensive review of the evaluation and treatment of recurrent aphthous stomatitis, providing healthcare professionals with the latest insights into this enigmatic condition. Participants will explore the diagnostic process, which relies on a thorough medical history and clinical findings. The program also delves into the various treatment modalities for RAS, emphasizing topical corticosteroids as the first-line approach and systemic steroids for more severe cases. Additionally, the use of immunosuppressants to prevent the formation of new RAS lesions and reduce the adverse effects associated with systemic steroids will be discussed. By participating in this activity, healthcare providers will gain a deeper understanding of RAS and its management, allowing them to provide more effective care for patients afflicted with this challenging condition.

Objectives:

Access free multiple choice questions on this topic.

Introduction

Recurrent aphthous stomatitis (RAS) is a chronic oral mucosa inflammatory disorder with an uncertain etiology.[1] Diagnosis is based on medical history and clinical findings. There seems to be a genetic predisposition to the condition, as up to 46% of patients report a family history of RAS.[2] Certain factors predispose to RAS, including local trauma, stress, smoking cessation, anemia, and hematinic deficiency.[3] Gastrointestinal conditions such as Chron disease, ulcerative colitis, and malabsorption diseases like celiac disease are also linked to the development of oral aphthous ulcers. Furthermore, RAS characterizes Behçet disease, and atypically severe RAS presentation may be a sign of HIV infection. Topical corticosteroids are the first line of treatment for managing RAS.[2][4] A short course of systemic steroids is reserved for more severe cases. Immunosuppressants are sometimes indicated to prevent the formation of new RAS lesions and decrease the prevalence of adverse effects experienced with systemic steroids.[5]

Etiology

The etiology of recurrent aphthous stomatitis remains imperfectly understood. The cause is believed to be multifactorial, involving a cell-mediated immunological reaction and a genetic predisposition. Histopathological changes are seen before ulceration occurs. Lymphocytes (mononuclear cells) infiltrate the oral epithelium, edema develops, and the keratinocytes (oral epithelial cells) undergo vacuolization and vasculitis. This results in localized swelling and later ulceration of the epithelium. Infiltration with neutrophils, lymphocytes, and plasma cells occurs before the epithelium heals and regenerates. The pathogenesis of RAS is a T-cell-mediated immunological reaction involving the inflammatory cytokine named tumor necrosis factor-alpha (TNF-α). TNF-α activates the chemotaxis of neutrophils, generating an acute inflammatory response and the expression of the major histocompatibility (MHC) complex.[3] Consequently, the epithelial cells are targeted for destruction by the CD8+ T cells.[6] Other cytokines, including interleukins IL-2, IL-10, IL-1b, and IL-6, may also be involved.[3]

It has also been suggested that the T-cell-mediated reaction seen in RAS is in response to Streptococcus sanguis antigens that cross-react with mitochondrial heat shock proteins, causing damage to the oral mucosa.[7]

There is a genetic predisposition to RAS; a family history of the condition is seen in 24% to 46% of patients.[2] These patients usually develop more rapid and severe ulceration.[3] A link to HLA-B51 and genes that control cytokines or heat shock proteins has been described.[8][9][10]

Predisposing Factors

Local

Local trauma predisposes to recurrent aphthous stomatitis in susceptible individuals or those with a hereditary predisposition to the disease.[11] RAS is less common in keratinized areas of the oral mucosa, including those of tobacco smokers.[3][2][12]

Systemic

Aphthous-like ulcerations may occur in various systemic diseases, including Behçet disease, nutritional deficiencies, gastrointestinal disorders, and primary and secondary immunodeficiencies, including HIV.[3]

Recurrent aphthous stomatitis is one of the criteria to diagnose Behçet disease.[2] Behçet disease is a chronic inflammatory condition of unknown etiology, which affects the oral mucosa, genitalia, eyes, skin, and joints.[13] Mucocutaneous lesions are the hallmarks of the condition and are usually the first to appear.[13] The development of oral aphthous ulcerations in combination with ulcers in other body parts should raise suspicion of Behçet disease.

Hematinic (iron, folic acid, or vitamin B12) and zinc deficiencies have been demonstrated in some patients with recurrent aphthous stomatitis.[3][14] Hematinic deficiencies occur twice as often in patients with RAS.[3] This may be because insufficient levels of hematinics can lead to anemia and a decreased capacity of the blood to oxygenate the oral mucosa, resulting in oral epithelial atrophy.[15] However, vitamin or iron supplementation does not always resolve lesions.[3]

Aphthous-like ulcers can be a sign of bowel disease, including Chron disease, gluten-sensitive enteropathy, and ulcerative colitis. However, the ulcerations can be due to malabsorption deficiencies in hematinics.[3][2]

Women during menstruation and menopause are more susceptible to recurrent aphthous stomatitis.[14] In contrast, those who are pregnant or taking the contraceptive pill frequently experience remission of the lesions, suggesting that hormonal imbalance may play a role in the pathogenesis of RAS.[14]

HIV patients have reduced CD4 lymphocyte and elevated CD8 lymphocyte levels, predisposing them to RAS.[16]

Epidemiology

Recurrent aphthous stomatitis is a relatively common condition, affecting up to 25% of the worldwide population.[3] It usually first appears in childhood or adolescence. It may develop as an individual entity or as part of a systemic condition, like Behçet disease. Out of the 3 subtypes, minor aphthous ulcers are the most prevalent (>70% of cases), whereas major (10%) and herpetiform (10%) types are less common.[17]

History and Physical

Recurrent aphthous stomatitis is characterized by persistent painful oral ulcers lasting days to months.[3] RAS is divided into 3 subgroups: minor aphthous ulcers, major aphthous ulcers, and herpetiform aphthous ulcers.

Minor Aphthous Ulcers

Minor aphthous ulcers are the most common type of RAS, affecting around 80% of RAS patients. They recur at 1 to 4-month intervals. The lesions are small (usually less than 5 mm in diameter), oval or round, and appear as a group of 1 to 6 ulcers at a time. The lesions are surrounded by an erythematous halo and covered by a grey-white pseudomembrane.[3]

Minor RAS mainly develops on non-keratinized mucosa, especially buccal and labial mucosa (see Image. Aphthous Ulcer) and the floor of the mouth, and heals within two weeks without scarring.[3] Oral discomfort may precede the aphthous lesions.

Major Aphthous Ulcers

Major aphthous ulcers (also known as periadenitis mucosa necrotica recurrent) are a more severe form of the disease and are seen in 10% of RAS patients.[17]

The ulcers are larger (>10 mm), last for 5 to 10 weeks, and usually leave scarring.[3] Any area of the mouth may be affected, including the oropharynx.[3]

Major aphthous ulcers are the most frequent type of RAS in patients with AIDS, and there is an increased link between these lesions and gastrointestinal and hematological disorders.[18] They do not usually follow a cyclical pattern.

Herpetiform Ulcers

Herpetiform ulceration is the least common type of RAS; it develops in around 1% to 10% of RAS patients.[3] The name derives from the resemblance to primary herpetic stomatitis; there is no connection to herpes viruses. Herpetiform ulcers have a predisposition for older females.[19]

The lesions appear as painful, small, and numerous ulcers. They may arise in numbers of up to 100 ulcers simultaneously, measuring 2 to 3 mm in diameter and lasting for one to two weeks.[3] The most frequent sites are the floor of the mouth and tongue (tip and lateral margins). They may appear on keratinized or non-keratinized mucosa. The small ulcers can sometimes fuse into a large and irregular ulcer, healing with scarring.[3]

Evaluation

Recurrent aphthous stomatitis is a clinical diagnosis.[3] However, excluding other causes of recurrent aphthous ulcers in the mouth is necessary, like Behçet disease, nutritional deficiencies, or inflammatory bowel disease, particularly when RAS develops suddenly in an adult patient.[14] Some RAS patients have anemia, hematinic, or dietary deficiencies; it is common practice to evaluate the complete blood count, red cell folate, and ferritin and vitamin B12 serum levels, which may also reveal gastrointestinal disorders.[3]

Treatment / Management

There is no specific management of recurrent aphthous stomatitis.[20] The best treatment is the one that controls the lesions for the longest time with few side effects.[21] Management is influenced by the intensity of the pain, frequency of episodes, and the patient's medical history and tolerability to medication.[4] Before initiating more directed treatment, it is essential to identify predisposing factors, if any, and control them.[4]

Treatment aims to alleviate symptoms, decrease the severity of the ulcers (number and size), promote healing, and prolong disease-free periods.[2][4] In general, milder episodes of RAS are managed with NSAIDs and topical corticosteroids, like benzydamine mouthwash and chlorhexidine mouthwash, to prevent added bacterial infection. Furthermore, a combination of topical tetracycline and steroids may be of value. A short course of systemic steroids, such as prednisone, is indicated for managing a severe episode of major aphthous ulcers.[22] Long-term systemic steroids are seldom recommended due to their serious adverse effects.[22] Herpetiform ulceration is usually managed in the same way as minor aphthous ulcers.

Chlorhexidine gluconate mouthwash and topical corticosteroids have been proven to decrease the severity of aphthous ulcers and shorten their duration. However, they do not affect the frequency of the outbreaks.[23] Chlorhexidine mouthwash reduces the bacterial load, protecting from bacterial superinfection of the ulcers and promoting healing.[2] Topical corticosteroids may stop the episode of aphthous ulcers when applied in the prodromal phase (when experiencing tingling or burning).[21]

The severity of the lesions and the frequency of episodes vary in each patient; treatment must be adjusted to the patient's needs. Classifying patients into 3 categories, each with a different treatment strategy (A, B, or C), is helpful.[4]

Type A

Patients in the type A category experience RAS episodes a few times a year, with outbreaks lasting only a few days and with mild pain.[4] As with all RAS cases, it is essential to identify precipitating factors and eliminate them, such as trauma-induced RAS, where a softer toothbrush can be recommended.[4] Medication may not be required.[4]

Type B

Patients in this category experience painful episodes of RAS monthly, lasting for 3 to 10 days.[4] Patients may have difficulty eating or toothbrushing due to pain.[4]

Treatment includes chlorhexidine mouthwash and a short course of topical corticosteroids immediately after the ulcers appear.[4] These patients usually require maintenance due to the recurrent pattern of the lesions.[4]

Alternative treatments include dexamethasone 0.05 milligrams/5 mL (rinse and spit 3 times daily) or a high-potency topical corticosteroid. For example, clobetasol ointment 0.05% in Orabase (1:1) or fluocinonide ointment 0.05% in Orabase (1:1) if the lesions recur on the same area, applied 3 times per day.[4]

If oral hygiene is deficient, professional cleaning by a dental hygienist must be considered after the ulcers have healed.[4]

In major aphthous ulcers, systemic corticosteroids may be indicated, but never exceeding more than 50 mg daily for 5 days.[4]

Type C

This category includes severely painful RAS lesions. There is no period without ulcers - a new one develops when one aphthous ulcer heals.[4] These patients are managed with topical and systemic corticosteroids and immunosuppressants like pentoxifylline, dapsone, and thalidomide.[4] Immunosuppressants are indicated to prevent the formation of new RAS lesions and decrease the prevalence of adverse effects experienced with systemic steroids.[5]

Differential Diagnosis

Systemic diseases resembling recurrent aphthous stomatitis include:[3]

Behçet disease: patients also have recurrent ulcerations in the genitalia, skin disorders (usually erythema nodosum or papulopustular lesions), ocular disease (usually posterior uveitis), and a variety of neurological, gastrointestinal, renal, hematological, or joint disorders.

MAGIC syndrome (Sweet syndrome): patients experience a sudden onset of fever, leucocytosis, and cutaneous lesions (well-demarcated plum-colored papules or plaques). Associated malignancy is seen in half of the patients.

PFAPA syndrome: includes periodic fever, pharyngitis, aphthae, and cervical adenitis. It occurs in young children; around two-thirds of cases improve with tonsillectomy.

Cyclic neutropenia: Patients develop fever, skin abscesses, lymphadenopathy, and respiratory tract infections. Besides oral ulceration, further oral complications may be seen, including severe gingivitis and aggressive periodontitis.

HIV disease

Prognosis

Recurrent aphthous stomatitis is a chronic condition that usually follows a cyclical pattern. The severity of the disease is typically related to the type of RAS. Minor RAS lesions tend to resolve in up to 2 weeks without scarring, whereas major RAS lesions are more persistent, healing with scarring after 6 weeks.[24] Herpetiform ulcers resolve in up to a month, and scarring is infrequent.[24]

Complications

The intensity of pain associated with the lesions is variable. Severe pain complicates drinking and eating, possibly leading to dehydration and nutritional deficiencies. Oral hygiene may also be impaired due to pain. There is a risk of bacterial superinfection of the aphthous ulcers, which is prevented with chlorhexidine mouthwash. Long-term maintenance with topical corticosteroids may lead to opportunistic fungal infections in the oral mucosa; therefore, a topical antifungal medication must be indicated for at least 2 weeks.[2]

Deterrence and Patient Education

Enhancing Healthcare Team Outcomes

Aphthous ulcers are common oral mucosa lesions of unknown etiology. These shallow ulcers are benign but have very high morbidity; an interprofessional team is recommended for management.

In most people, aphthous ulcers are recurrent and often take 1 to 3 weeks to resolve. However, the ulcer-free period varies from individual to individual. The choice of treatment depends on the severity and personal experience. Unfortunately, there is no single therapy that works for every case. Patient education by a team of clinicians, nurses, and pharmacists is the key to preventing morbidity.

Many RAS patients have systemic disorders, like diabetes mellitus, celiac disease, inflammatory bowel disease, and liver or kidney disease, and must be referred to an appropriate physician for further management. The outcomes of recurrent aphthous stomatitis depend on the type of ulceration and predisposing factors. Prompt consultation with an interprofessional group of specialists is recommended to improve outcomes. [Level 3]

Review Questions

Aphthous Ulcer

Figure

Aphthous Ulcer. This minor ulcer is shown on the labial mucosa. Contributed by Melina Brizuela, BDS

References

Sánchez-Bernal J, Conejero C, Conejero R. Recurrent Aphthous Stomatitis. Actas Dermosifiliogr (Engl Ed). 2020 Jul-Aug;111(6):471-480. [PubMed: 32451064]

Chiang CP, Yu-Fong Chang J, Wang YP, Wu YH, Wu YC, Sun A. Recurrent aphthous stomatitis - Etiology, serum autoantibodies, anemia, hematinic deficiencies, and management. J Formos Med Assoc. 2019 Sep;118(9):1279-1289. [PubMed: 30446298]

Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg. 2008 Apr;46(3):198-206. [PubMed: 17850936]

Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc. 2003 Feb;134(2):200-7. [PubMed: 12636124]

Mimura MA, Hirota SK, Sugaya NN, Sanches JA, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). 2009;64(3):193-8. [PMC free article: PMC2666466] [PubMed: 19330244]

Savage NW, Seymour GJ, Kruger BJ. Expression of class I and class II major histocompatibility complex antigens on epithelial cells in recurrent aphthous stomatitis. J Oral Pathol. 1986 Apr;15(4):191-5. [PubMed: 3088233]

Hasan A, Childerstone A, Pervin K, Shinnick T, Mizushima Y, Van der Zee R, Vaughan R, Lehner T. Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Clin Exp Immunol. 1995 Mar;99(3):392-7. [PMC free article: PMC1534212] [PubMed: 7533679]

Shohat-Zabarski R, Kalderon S, Klein T, Weinberger A. Close association of HLA-B51 in persons with recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol. 1992 Oct;74(4):455-8. [PubMed: 1408019]

Bazrafshani MR, Hajeer AH, Ollier WE, Thornhill MH. Recurrent aphthous stomatitis and gene polymorphisms for the inflammatory markers TNF-alpha, TNF-beta and the vitamin D receptor: no association detected. Oral Dis. 2002 Nov;8(6):303-7. [PubMed: 12477062]

Mizuki N, Ohno S, Sato T, Ishihara M, Miyata S, Nakamura S, Naruse T, Mizuki H, Tsuji K, Inoko H. Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behçet's disease. Hum Immunol. 1995 Jun;43(2):129-35. [PubMed: 7591872]

Huling LB, Baccaglini L, Choquette L, Feinn RS, Lalla RV. Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med. 2012 Feb;41(2):149-52. [PMC free article: PMC3323121] [PubMed: 22077475]

Baş Y, Seçkin HY, Kalkan G, Takcı Z, Önder Y, Çıtıl R, Demir S, Şahin Ş. Investigation of Behçet's Disease and Recurrent Aphthous Stomatitis Frequency: The Highest Prevalence in Turkey. Balkan Med J. 2016 Jul;33(4):390-5. [PMC free article: PMC5001815] [PubMed: 27606133]

Alpsoy E. Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016 Jun;43(6):620-32. [PubMed: 27075942]

Slebioda Z, Szponar E, Kowalska A. Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review. Arch Immunol Ther Exp (Warsz). 2014 Jun;62(3):205-15. [PMC free article: PMC4024130] [PubMed: 24217985]

Sun A, Lin HP, Wang YP, Chiang CP. Significant association of deficiency of hemoglobin, iron and vitamin B12, high homocysteine level, and gastric parietal cell antibody positivity with atrophic glossitis. J Oral Pathol Med. 2012 Jul;41(6):500-4. [PubMed: 22188475]

Chiang CP, Chueh LH, Lin SK, Chen MY. Oral manifestations of human immunodeficiency virus-infected patients in Taiwan. J Formos Med Assoc. 1998 Sep;97(9):600-5. [PubMed: 9795527]

Belenguer-Guallar I, Jiménez-Soriano Y, Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. J Clin Exp Dent. 2014 Apr;6(2):e168-74. [PMC free article: PMC4002348] [PubMed: 24790718]

Kerr AR, Ship JA. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol. 2003;4(10):669-80. [PubMed: 14507229]

Scully C, Porter S. Recurrent aphthous stomatitis: current concepts of etiology, pathogenesis and management. J Oral Pathol Med. 1989 Jan;18(1):21-7. [PubMed: 2664131]

Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Feb;81(2):141-7. [PubMed: 8665304]

Chavan M, Jain H, Diwan N, Khedkar S, Shete A, Durkar S. Recurrent aphthous stomatitis: a review. J Oral Pathol Med. 2012 Sep;41(8):577-83. [PubMed: 22413800]

Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am. 2014 Apr;58(2):281-97. [PMC free article: PMC3964366] [PubMed: 24655523]

Porter SR, Scully Cbe C. Aphthous ulcers (recurrent). BMJ Clin Evid. 2007 Jun 01;2007 [PMC free article: PMC2943778] [PubMed: 19454082]

Edgar NR, Saleh D, Miller RA. Recurrent Aphthous Stomatitis: A Review. J Clin Aesthet Dermatol. 2017 Mar;10(3):26-36. [PMC free article: PMC5367879] [PubMed: 28360966]

Disclosure: Michael Plewa declares no relevant financial relationships with ineligible companies.

Disclosure: Kingshuk Chatterjee declares no relevant financial relationships with ineligible companies.